Deals: Page
-
Lonza snatches Shire facility as biologics manufacturing rakes in returns
The drug developer expects the new site will complement operations from another mammalian manufacturing plant in the U.K.
By Jacob Bell • Oct. 5, 2017 -
Amgen digs deeper in I/O with CytomX deal
More than a billion dollars in milestone payments is on the line as the drugmakers work on developing therapies using CytomX's Probody technology.
By Jacob Bell • Oct. 4, 2017 -
Getty and BioPharma Dive
Celgene snaps up Nimbus assets in immunology deal
The deal gives the big biotech access to Nimbus' deep computational expertise and options to programs from the alliance.
By Suzanne Elvidge • Oct. 4, 2017 -
Endocyte shares shoot up on prostate cancer pact
The Indiana biopharma aims to pivot from R&D setbacks with a licensing deal for a new lead candidate.
By Suzanne Elvidge • Oct. 3, 2017 -
Elizabeth Regan/BioPharma Dive
In RARE news, Dimension dumps Regenxbio for better offer
Ultragenyx's superior offer has trumped the previously announced deal for the gene therapy developer.
By Suzanne Elvidge • Oct. 3, 2017 -
Prescribed Reading: No such thing as unicorns
Both closely watched Axovant and Intarcia had major setbacks this week, despite high hopes that their therapies would be game-changers.
By Lisa LaMotta • Sept. 29, 2017 -
Elizabeth Regan/BioPharma Dive
Arcturus to go public through merger with Alcobra
Combining with Alcobra will give currently private Arcturus access to public markets, while adding cash for development of its RNA-focused pipeline.
By Suzanne Elvidge • Sept. 29, 2017 -
NewLink inks deal with AstraZeneca to test Imfinzi combo
IDO inhibitors like NewLink's indoximod are seen as a potentially fruitful pairing for PD-L1 inhibitors.
By Suzanne Elvidge • Sept. 27, 2017 -
Prescribed Reading: Consolidation, clinical holds and landmark results
The FDA continues its clinical hold spree for PD-1/L1s, consolidation is rampant in the CDMO space and RNAi may become a reality very soon.
By Lisa LaMotta • Sept. 22, 2017 -
Cellectar, Onconova partner on cancer drug conjugates
An early-stage collaboration could boost the two small-cap biotechs' pipelines.
By Suzanne Elvidge • Sept. 22, 2017 -
Taiho taps Arcus in latest I/O deal
The two biotechs have inked a development and commercialization agreement for immuno-oncology assets in Asia.
By Suzanne Elvidge • Sept. 21, 2017 -
Swedish CDMO picks up facility, supply contract in deal with Roche
Roche has offloaded several small molecule-focused sites in a shift toward biologics production.
By Suzanne Elvidge • Sept. 21, 2017 -
Teva teams up with Nuvelution in Tourette
The companies are planning a late-stage program that will evaluate Austedo, which has already locked down two indications this year, as a treatment for children with the syndrome.
By Suzanne Elvidge • Sept. 20, 2017 -
Elizabeth Regan/BioPharma Dive
Catalent adds biologics manufacturing with $950M Cook Pharmica deal
The contract developer is building out its capabilities to encompass development through commercialization.
By Lisa LaMotta • Sept. 19, 2017 -
Teva offloads the rest of its women's health business for $1.4B
The deals put Teva past its goal of selling $2 billion worth of assets by year's end.
By Jacob Bell • Sept. 19, 2017 -
Ultragenyx trying to snag Regenxbio's takeover target
Dimension Therapeutics now has another buyout offer to consider.
By Jacob Bell • Sept. 18, 2017 -
AstraZeneca's latest sale rakes in $555M
The British pharma has been monetizing older, non-core assets as it focuses on core therapeutic areas.
By Lisa LaMotta • Sept. 14, 2017 -
Bristol, Roche tap Halozyme for tech platform
Between upfront, milestone and royalty payments, the separate licensing agreements could be worth more than $2 billion combined.
By Jacob Bell • Sept. 14, 2017 -
Elizabeth Regan/BioPharma Dive
Onxeo finds a partner to progress its cancer medication
A licensing deal with private drugmaker Monopar should help the Paris-based company push Validive into late-stage testing.
By Jacob Bell • Sept. 13, 2017 -
Elizabeth Regan/BioPharma Dive
Sobi looking to make a deal, report says
The Swedish rare disease drugmaker could be looking to boost revenues through M&A, according to an analyst.
By Lisa LaMotta • Sept. 12, 2017 -
Teva begins paying down debt with $1.1B deal
The beleaguered Israeli company has $34 billion in debt and intends to sell off non-core assets to help rightsize its balance sheet.
By Lisa LaMotta • Sept. 12, 2017 -
Prescribed Reading: PD-1, CAR-T threatened by clinical holds
Highly innovative oncology technologies may be life-saving, but they have also raised major safety concerns.
By Lisa LaMotta • Sept. 8, 2017 -
Merck picks up new I/O approach
The big pharma is further growing its I/O portfolio by acquiring RIG-I targeting therapeutics startup Rigontec.
By Suzanne Elvidge • Sept. 7, 2017 -
Bioverativ and Bicycle keep rare disease deals rolling
Through a new research collaboration, the companies are looking for new treatments for hemophilia as well as the more common sickle cell disease.
By Jacob Bell • Sept. 6, 2017 -
3SBio snaps up Therapure CDMO for $290M
The Chinese company looks to the West for further expansion into drug development and manufacturing.
By Suzanne Elvidge • Sept. 5, 2017
Previous
